SCHEMBL732334

SCHEMBL732334

COc1cc(C(=O)O)cc(-c2ccccc2)n1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTRC Q99895 2/20 0.56
ALDH1A1 P00352 2/20 0.55
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
KDM4E B2RXH2 2/20 0.50
MCL1 Q07820 2/20 0.50
MEN1 O00255 1/20 0.50
MAPT P10636 1/20 0.50
TSHR P16473 1/20 0.50
KMT2A Q03164 1/20 0.50
ATM Q13315 1/20 0.50
PDE10A Q9Y233 2/20 0.48
LMNA P02545 3/20 0.46
TDP1 Q9NUW8 1/20 0.46
ADORA3 P0DMS8 3/20 0.46
ADORA1 P30542 2/20 0.44
GAA P10253 1/20 0.44
ADORA2A P29274 1/20 0.44
LTB4R Q15722 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28493223 0.88 ALDH1A1 (0.70) ALDH1A1NPC1RAB9AKDM4EMEN1
SCHEMBL14241164 0.85 ADORA3 (0.50) CTRCALDH1A1NPC1RAB9AKDM4E
SCHEMBL14226764 0.85 ALDH1A1 (0.50) CTRCALDH1A1NPC1RAB9AKDM4E
SCHEMBL18019283 0.83 CHEK1 (0.50) CTRCALDH1A1NPC1RAB9AKDM4E
SCHEMBL4259978 0.82 CTRC (0.77) CTRCALDH1A1NPC1RAB9AKDM4E
SCHEMBL668838 0.82 KDM4E (0.69) ALDH1A1KDM4ETSHRLMNATDP1
SCHEMBL899267 0.81 KDM4E (0.44) CTRCALDH1A1NPC1RAB9AKDM4E
SCHEMBL15131385 0.81 RXRA (0.45) ALDH1A1NPC1RAB9AKDM4EMEN1
SCHEMBL20256996 0.81 SYK (0.43) ALDH1A1KDM4EMAPTLMNAADORA3
SCHEMBL21172189 0.80 ACACB (0.47) CTRCALDH1A1NPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
WO-2012168820-A1 POLYMYXIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS PFIZER INC. (US) 2012-12-13 WO disclosed
WO-2012168820-A1 POLYMYXIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS PFIZER INC. (US) 2012-12-13 WO disclosed
US-20120316105-A1 Polymyxin Derivates Useful As Antibacterial Agents PFIZER INC. 2012-12-13 US disclosed
US-20120316105-A1 Polymyxin Derivates Useful As Antibacterial Agents PFIZER INC. 2012-12-13 US disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 CTRC 1990/4885ALDH1A1 113/4885NPC1 2438/4885
US-20120316105-A1 Polymyxin Derivates Useful As Antibacterial Agents NPEPPS, MDN1, PNKP CTRC 2022/4885ALDH1A1 4774/4885NPC1 3863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.